Among them, the inhibitor targeting EGFR tyrosine kinase (EGFR-TKI), which inhibits EGFR signaling overactivation, has demonstrated remarkable efficacy in NSCLC patients with EGFR-activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.